Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2842)	6/15/2010 11:56:49 AM
From: Jibacoa	Respond to of 3722

ABIO was up 14.84% and is still up 8.33% at present.<g> Volume remains low about 0.32x its ADV bigcharts.marketwatch.com The stock is still trying to get off from the DT coming from the March 26 H when the stock spiked to $9.23 <G> bigcharts.marketwatch.com As mentioned, back in March, ABIO was awarded a patent on methods of treating heart failure patients with bucindolol based on genetic testing. Bucindolol supposedly is unique among beta-blockers bcause it has been shown to lower systemic norepinephrine levels and facilitate conversion of constitutively active beta-1 Arg receptors to an inactive state,which may explain its more favorable response in the beta-1 389 Arg/Arg genotype versus the response in another common genotype of the beta-1 receptor known as 389 Gly. On May 17 ABIO said said that it reached an agreement with the FDA on the design of a trial to test its experimental treatment for heart failure, with the stock spiking to %5.56 <g> According to the special protocol agreement, bucindolol, will be evaluated in a trial that plans to enroll 3,200 patients with chronic CHF who have the specific genotype that appears to respond most favorably to the drug. The main goal of the trial, which will compare bucindolol with metoprolol CR/XL, looking at a cardiovascular mortality and cardiovascular hospitalization. If the results of either of the interim analyses meet the pre-specified criteria, ABIO would be able to formally submit a complete response to the FDA’s May 2009 Complete Response Letter and the results of the interim analysis could serve as the clinical effectiveness basis for FDA approval. It is estimated that the trial will take 3.5 years. ABIO's goal is to have bucindolol commercially available soon after the conclusion of the trial. The ACYAY is $0.50 The ACTAY is $0.50 The short ratio was up 33% in the last month. Although the stock traded at $986 in Jan2001 and $419.40 in August 2006, it seems better to wait for further news and to see if the stock can test again the $6 level.<g> bigcharts.marketwatch.com Bernard